持续药物治疗用于年轻女性持续性早期子宫内膜癌
该回顾性研究分析51例 presumed stage IA、1或2级子宫内膜样腺癌患者,这些患者在至少9个月孕激素治疗后9-12个月活检仍持续存在病变。多因素分析显示12个月时未达部分缓解是 prolonged 孕激素治疗后未达完全缓解的独立预后因素。
要点
- 至少9个月孕激素治疗后持续存在的早期子宫内膜癌,继续内分泌治疗可使72.5%患者达到完全缓解
- 中位至完全缓解时间为17.3个月,范围12.1-91.7个月
- 12个月时未达部分缓解是继续孕激素治疗后未达完全缓解的独立预后因素
核心结论
- 对于希望保留生育功能的年轻女性,至少9个月孕激素治疗后仍持续存在的早期子宫内膜癌,继续内分泌治疗是有效的。
研究设计与样本
- 回顾性分析51例 presumed stage IA、grade 1或2子宫内膜样腺癌患者,这些患者在至少9个月孕激素为基础的治疗后9-12个月活检显示持续病变。
主要发现
- 从开始初始孕激素治疗至完全缓解的中位时间为17.3个月(范围12.1-91.7个月)。
- 单因素分析显示多囊卵巢综合征病史、组织学2级、12个月时未达部分缓解与未达完全缓解显著相关(OR 6.188,95%CI 1.405-27.244,p=0.018;OR 9.722,95%CI 1.614-58.581,p=0.013;OR 21.750,95%CI 4.016-117.783,p<0.001)。
- 多因素分析显示12个月时未达部分缓解是延长孕激素治疗后未达完全缓解的独立预后因素(OR 21.803,95%CI 3.601-132.025,p=0.001)。
临床怎么用
- 对年轻、要求保留生育功能的早期子宫内膜癌患者,若至少9个月孕激素治疗后病变持续存在,可考虑继续内分泌治疗而非立即手术。
- 治疗过程中应关注12个月时是否达到部分缓解,未达部分缓解者后续完全缓解可能性显著降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to investigate the effectiveness of continuing medical therapy in patients who did not achieve complete response (CR) despite 9 months of progestin treatment. We also sought to determine the prognostic factors associated with achieving CR among these patients. METHODS: We retrospectively analyzed 51 patients with presumed stage IA, grade 1 or 2 endometrioid adenocarcinoma who had persistent disease on biopsy performed at 9-12 months after at least 9 months of progestin-based therapy. Data on clinicopathological factors and oncological and obstetrical outcomes following continuous hormonal treatment were extracted from the patients' medical records and analyzed. Univariate and multivariate analyses for predicting CR were performed. RESULTS: Thirty-seven (72.5%) of 51 patients achieved CR after prolonged fertility-sparing treatment. Median time to CR from starting initial progestin was 17.3 months (range, 12.1-91.7 months). On univariate analysis, history of polycystic ovarian syndrome, histologic grade 2, and not achieving partial response (PR) until 12 months were significantly associated with failure to CR (odds ratio [OR], 6.188, 95% confidence interval [CI], 1.405-27.244, p = 0.018; OR, 9.722, 95% CI, 1.614-58.581, p = 0.013; and OR, 21.750, 95% CI, 4.016-117.783, p < 0.001, respectively). Multivariate analysis revealed that not achieving PR until 12 months was an independent prognostic factor predicting failure to CR after prolonged progestin therapy (OR, 21.803, 95% CI, 3.601-132.025, p = 0.001). CONCLUSIONS: Continued medical treatment is effective for persistent early endometrial carcinoma after at least 9 months of progestin therapy in young women who want to preserve their fertility.
引用
- Cho A, Lee SW, Park JY, et al. Continued medical treatment for persistent early endometrial cancer in young women. Gynecol Oncol. 2020. PMID: 33246662. doi:10.1016/j.ygyno.2020.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。